$DXCM

Brown Michael Jon sold $127K of DXCM

Brown Michael Jon (EVP Chief Legal Compliance Off) sold 1,700 shares of DEXCOM INC (DXCM) at $74.42 ($0.13M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brown Michael Jon
Published Jul 16, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DXCM
Neutral
high confidence
Mentioned
$DXCM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DXCMNeutralLow
01

Why it matters

The disclosure updates insider ownership records but does not introduce new guidance, trial results, regulatory actions, or deal activity.

02

Market read

Traders may note the insider sale for positioning or sentiment, but it is unlikely to change the fundamental outlook.

03

What to watch

The transaction is explicitly under a pre-arranged 10b5-1 plan, which reduces interpretability versus discretionary selling.

Relevance 3/10Novelty 2/10Timing: Filed after-hours on 2026-07-16, reflecting a sale executed 2026-07-15.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for DexCom.

Company-level read

Ticker impact

$DXCMNeutralHigh confidence
Context

DexCom Form 4 shows EVP Chief Legal Compliance Off Brown sold 1,700 shares at $74.42 on a 10b5-1 plan, totaling $126,514.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is an open-market sale by an insider, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No meaningful read-across to the medical device or diabetes monitoring sector from a single routine 10b5-1 sale.

None.

None.

Counterpoint

Some traders may still treat insider selling as a weak sentiment signal, especially if multiple recent filings show net selling, but this article alone does not establish that pattern.

Key entities

  • DexCom

    Public company subject of the Form 4 insider transaction disclosure.

  • Michael Jon Brown

    EVP, Chief Legal Compliance Officer who executed the reported sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DXCMMed

DexCom (DXCM) Tests Its Execution Story After Expanding Its CFO Role

DexCom (DXCM) promoted its CFO, Jereme Sylvain, to also serve as COO, expanding his role to include global operations and quality. The company's stock has seen volatility, with a 3.1% drop over the past week and a 30.2% gain year-to-date. Analysts suggest a fair value of $94.48, indicating a modest discount at the current price of $86.62.

$DXCMLow

Did COO Appointment Just Shift DexCom (DXCM) Investment Narrative?

DexCom (DXCM) appointed Jereme Sylvain as COO and Glenn Boehnlein to its board, focusing on execution, supply chain, and capital allocation. The company projects $6.8B revenue and $1.5B earnings by 2029, with analysts expecting 11.2% yearly growth. Investors watch leadership changes for impact on expansion and execution.

$DXCMLow

DexCom (DXCM) Reshuffles Leadership, Is The Stock Fully Valued?

DexCom (DXCM) promoted CFO Jereme Sylvain to CFO and COO, added Glenn S. Boehnlein to its board. The stock trades at $87.93, up 21.33% over 90 days and 32.15% year-to-date. Analysts estimate fair value at $94.12, with growth driven by expanded insurance coverage and global market penetration. The company trades at a P/E of 33.2x, above sector and peer averages.

$DXCMMed

Dexcom CFO to expand into COO role

Dexcom's CFO, Jereme Sylvain, will also take on the role of COO, overseeing global operations and quality teams. The move comes as the company develops its G8 continuous glucose monitor and expands its Stelo wearable. Previous COO Jake Leach became CEO in January.

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.